TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04675944
Drug: BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (2 x 100 mg tablets), oral route
Study: NCT01498497
Drug: EUR-1100
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01498497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890368
Drug: TTI-621 + PD-1/PD-L1 Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
Study: NCT02536430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: buccal infiltration of Normal Saline.
Study: NCT01241435
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01128530
Drug: JNJ-32729463 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet twice daily
Study: NCT01586299
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg every 8 hours until 24 hours after resolution of fever
Study: NCT01586299
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg every 6 hours until 24 hours after resolution of fever
Study: NCT00765934
Drug: Rapydan
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine / tetracaine 70/70 mg patch
Study: NCT01284517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent to Lurasidone dosing
Study: NCT04140396
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion at 10mL/hour
Study: NCT03583112
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral one placebo tablet before MRI scan.
Study: NCT02339441
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
Study: NCT03354039
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
Study: NCT02339441
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
Study: NCT03117816
Drug: AOP2014 / Pegylated-Proline-interferon alpha-2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
Study: NCT03527472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
Study: NCT04085276
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 240mg, i.v., q3w; Other name: Toripalimab
Study: NCT04085276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, i.v., q3w;
Study: NCT04170543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02586623
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00428948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as tablets.
Study: NCT01926834
Drug: Erigeron Injection
Normalized name: ERIGERON CANADENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erigeron Injection, 30ml, iv, qd, for 7days
Study: NCT01926834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline, 500ml,i.v.,qd, for 7 days
Study: NCT02975349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were administered for 24 weeks
Study: NCT00004266
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02315417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03254199
Drug: Placebo ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ODT taken three times daily for 28 days
Study: NCT00854880
Drug: PDC339
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00854880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00556894
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT00556894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT04393493
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 50 mg pill administrated every 24 hours in group B
Study: NCT00108836
Drug: XBD173
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02982642
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
Study: NCT04173403
Drug: 450mg AK102
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK102 Q4W
Study: NCT04173403
Drug: 150mg AK102
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK102 Q2W
Study: NCT00102063
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet po qd x 42 days
Study: NCT02337569
Drug: NPC-02
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337569
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393377
Drug: fluvastatin 10 mg and valsartan 20 mg
Normalized name: fluvastatin 20 MG
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00756730
Drug: ATV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Study: NCT00756730
Drug: DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Study: NCT00149838
Drug: Antidepressant Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
Study: NCT04417361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Study: NCT01125800
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
Study: NCT01688089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01688089
Drug: Levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00177216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
Study: NCT01315314
Drug: Balance, Fresenius Medical Care, Germany
Approvals — FDA: no, EMA: no, PMDA: no
Description: low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
Study: NCT04042545
Drug: PPP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
Study: NCT04042545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
Study: NCT03383146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously twice daily.
Study: NCT01862536
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use in double blind study.
Study: NCT03601910
Drug: D308 10mg Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: D308 10mg Tab.1T single oral administration under fasting condition
Study: NCT03601910
Drug: CKD-380 10mg Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
Study: NCT00967512
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
Study: NCT01846689
Drug: ESS (medical food/drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription medical food erythropoietin stimulating system
Study: NCT02237365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
Study: NCT04332107
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be shipped a single 1.2 g dose of oral azithromycin
Study: NCT04332107
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be shipped a dose of matching placebo
Study: NCT02052752
Drug: Neutrogena Rapid Clear®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study: NCT02348593
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01223690
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
Study: NCT01223690
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
Study: NCT00479713
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
Study: NCT00479713
Drug: Comparator : rosuvastatin calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10mg. The treatment duration will be 6 weeks.
Study: NCT00479713
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
Study: NCT00479713
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
Study: NCT00149890
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
Study: NCT00853866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 80 min before assessment of Jebsen Taylor test
Study: NCT04503265
Drug: AMXI-5001:Dose Escalation Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Study: NCT04503265
Drug: AMXI-5001:Dose Expansion Phase II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Study: NCT04135378
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
Study: NCT01152190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 8 weeks
Study: NCT01595321
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
Study: NCT01595321
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus.
Study: NCT00834834
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
Study: NCT00687388
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg daily for 8 weeks
Study: NCT00687388
Drug: alpha-blocker and NSAID
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
Study: NCT02801071
Drug: 15g L-citrulline daily p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02801071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03140657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
Study: NCT00092755
Drug: MK0663, etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092755
Drug: Comparators: ibuprofen and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01291563
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets of TMC207 (100 mg/tablet) on Day 1
Study: NCT01291563
Drug: TMC207 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets of TMC207 placebo on Day 1
Study: NCT02315833
Drug: Acetium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration contains L-cysteine 100mg
Study: NCT02315833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule matching Acetium for oral administration.
Study: NCT03824457
Drug: Rheosorbilact®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Study: NCT03824457
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Study: NCT03512756
Drug: Capecitabine, Gemcitabine, and 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU
Study: NCT01348880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo to match 10 mg vardenafil ODT. taken without water
Study: NCT03860844
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03860844
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study: NCT02845999
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: day -6 : cyclophosphamide 60 mg/Kg
Study: NCT00411099
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01209039
Drug: GSK1144814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of GSK1144814 for 14 days
Study: NCT01209039
Drug: GSK1144814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
Study: NCT03463135
Drug: Placebo for GLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
Study: NCT02517697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral formulation of matching placebo three times daily for 12 weeks
Study: NCT02001935
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
Study: NCT04656886
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00284700
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04487236
Drug: ZN-A-1041 50mg BID
Normalized name: zinc acetate 50 MG
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally 21days for one cycle
Study: NCT04487236
Drug: ZN-A-1041 100mg BID
Normalized name: dimethicone 10 MG/ML / zinc oxide 100 MG/ML [A+D Diaper Rash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 21days for one cycle
Study: NCT04487236
Drug: ZN-A-1041 200mg BID
Normalized name: zinc undecylenate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 21days for one cycle
Study: NCT04487236
Drug: ZN-A-1041 400mg BID
Normalized name: zinc oxide 400 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 21days for one cycle
Study: NCT04487236
Drug: ZN-A-1041 600mg BID
Normalized name: VITAMIN A/VITAMIN D/ZINC OXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 21days for one cycle
Study: NCT04487236
Drug: ZN-A-1041 800mg BID
Normalized name: VITAMIN A/VITAMIN D/ZINC OXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 21days for one cycle
Study: NCT04487236
Drug: ZN-A-1041 1000mg BID
Normalized name: zinc-DTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally 21days for one cycle
Study: NCT00396851
Drug: Gurmar
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01310465
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
Study: NCT00129948
Drug: Troxatyl™ (troxacitabine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00616733
Drug: CS-0777 tablets
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg, once-weekly, for 12 weeks
Study: NCT00616733
Drug: CS-0777 tablets
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
Study: NCT00771199
Drug: Transdermal Therapeutic System (TTS)-Fentanyl
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
Study: NCT00649506
Drug: Macrodantin® 100 mg Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT03777059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching atogepant tablets
Study: NCT01984086
Drug: Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study: NCT01984086
Drug: Salbutamol Sulphate UD-DPI Blister (selected from Part A)
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation will be determined depending on the outcome of Part A.